DrugPatentWatch Database Preview
Details for New Drug Application (NDA): 040793
NDA 040793 describes A-METHAPRED, which is a drug marketed by Abbott, Hospira, and Hospira Inc, and is included in fourteen NDAs. Additional details are available on the A-METHAPRED profile page.
The generic ingredient in A-METHAPRED is methylprednisolone sodium succinate. There are forty drug master file entries for this compound. Eleven suppliers are listed for this compound. Additional details are available on the methylprednisolone sodium succinate profile page.
The generic ingredient in A-METHAPRED is methylprednisolone sodium succinate. There are forty drug master file entries for this compound. Eleven suppliers are listed for this compound. Additional details are available on the methylprednisolone sodium succinate profile page.
Summary for 040793
| Tradename: | A-METHAPRED |
| Applicant: | Hospira Inc |
| Ingredient: | methylprednisolone sodium succinate |
| Patents: | 0 |
| Therapeutic Class: | Hormonal Agents, Stimulant/Replacement/Modifying (Adrenal) Inflammatory Bowel Disease Agents |
| Formulation / Manufacturing: | see details |
Profile for product number 001
| Active Rx/OTC/Discontinued: | DISCN | Dosage: | INJECTABLE;INJECTION | Strength | EQ 40MG BASE/VIAL | ||||
| Approval Date: | Nov 25, 2008 | TE: | RLD: | No | |||||
Complete Access Available with Subscription
